International Stereotactic Radiosurgery Society

Become a member | Log In | Contact us

The ISRS webinar series began in 2016. We have already delivered over 30 webinars on intracranial and body SRS and from experts around around the world.

A video replay of each past webinar is available to ISRS members.

Next Webinars

August 17, 2018

Treatment of Uveal Metastases with Gamma Knife SRS by Edward MONACO

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

Uveal metastases from systemic cancer (to the iris, ciliary body, or choroid) are not infrequent ophthalmologic events.  Treatment options have consisted of enucleation, systemic chemotherapy, plaque brachytherapy, and fractionated external beam radiation.  Although SRS with the Gamma Knife is an accepted treatment for primary uveal melanoma with good efficacy and safety, its documented use in the treatment of uveal metastases is lacking.  In this webinar, the indications, technique, and outcomes of treatment of uveal metastases with the Gamma Knife will be explored.

August 23, 2018

Prostate radiosurgery by Maris MEZECKIS

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

The webinar will cover the following items:

  • evidence for hypofractionation for prostate cancer
  • technical aspects (marker implantation, imaging, patient preparation, tracking the prostate)
  • the role of PET-CT in prostate radiosurgery
  • homogenous and heterogenous (HDR-like) dose distribution
  • future perspectives of prostate SRS (the role of SRS in high-risk prostate cancer, potency sparing, further hypofractionation etc.)

September 04, 2018

SBRT for early stage lung cancer by Nikolay VOROBYOV

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

Stereotactic body radiotherapy (SBRT), is now a standard treatment option for patients with stage I non-small cell lung cancer or oligometastatic lung tumor who are medically inoperable or medically operable but refuse surgery. SBRT is extremely well tolerated, is an outpatient procedure, and has been reported to yield local tumor control rates exceeding 90%: it is an attractive alternative to an invasive surgical procedure.

The webinar will cover the following items: 

  • SBRT use in operable tumors
  • SBRT for central tumors
  • Possible role of SBRT in oligometastatic lung disease
  • Role of CT and PET in differentiating tumor recurrence from radiation fibrosis
  • Proton SBRT

September 24, 2018

A Bright Future Ahead Using Radiotherapy for Prostate Cancer by Robert TIMMERMAN

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

Historically, improved technologies were used primarily to deliver a higher total dose of radiotherapy (RT) for prostate cancer.  For lower risk groups, such protracted RT is well tolerated but inconvenient and costly.  These same risk groups migrated to surgery in the 1990s with the promise of preserving potency with the “nerve-sparing prostatectomy.” Long term data shows potency is far from preserved with surgery.  More recently, many higher risk patients have also migrated to surgery justified by the notion that RT cannot control high grade tumor.  We’ll discuss how current shortcomings constitute future opportunities.  Clinical research has shown that shorter RT courses are just as effective.  Even ablative radiation can be safely delivered with ultimate convenience and potential to address high risk disease.  Indeed, better delineation of anatomy and shaping of dose might actually deliver a true, potency preserving treatment.  Improved technologies such as image guidance and protons could achieve even more if used prudently.

November 09, 2018

SRS for meningiomas by John SUH

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 11:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

December 05, 2018

Synergy of Immunotherapy and SRS by Daniel TRIFILETTI

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 11:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

Stereotactic radiosurgery has been proposed as a method to create a personalized, in situ tumor vaccine, allowing for the patient’s innate immune system to target malignant cells within and well outside of the radiosurgical target (either intracranial or extracranial). This brief lecture will summarize this biologic rationale, existing clinical data to date, as well as future unanswered questions.

January 28, 2019

Radiosurgery for Rare Skull base Tumours by Dade LUNSFORD

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 11:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

In this presentation Professor Lunsford will discuss outcome studies  of both his center at UPMC  as well as multicenter   studies from the International Radiosurgery Research Foundation related to glomus tumors, chordoma, chondrosarcoma, foramen magnum meningiomas, and lower cranial nerve schwannomas.  Frame based SRS approaches, targeting, dose prescription, and the importance of both conformality and selectivity will be emphasized. In order to preserve existing cranial nerve function and acheive long term tumor control, SRS is often the most effective and safest management strategy.